Abstract LB-333: PARP-1 supports HPV infection and HPV-associated head and neck cancerPan C, Biktasova A, Hajek M, Sewell A, Sathe T, Bellinger G, Yarbrough W, Issaeva N. Abstract LB-333: PARP-1 supports HPV infection and HPV-associated head and neck cancer Cancer Research 2018, 78: lb-333-lb-333. DOI: 10.1158/1538-7445.am2018-lb-333.
Abstract 4588: Identification of CDCP1 as a HIF-2α target gene involved in the regulation of cancer cell migration and metastasis.Emerling B, Benes C, Bell E, Poulogiannis G, Courtney K, Lui H, Choo-Wing R, Bellinger G, Soltoff S, Cantley L. Abstract 4588: Identification of CDCP1 as a HIF-2α target gene involved in the regulation of cancer cell migration and metastasis. Cancer Research 2013, 73: 4588-4588. DOI: 10.1158/1538-7445.am2013-4588.
Abstract LB-365: Effective use of PI3K/MTOR and MEK inhibitors prior to hormone ablative therapy in PTEN-loss driven murine prostate cancerPatnaik A, Courtney K, Robichaud K, Bellinger G, Nardella C, Signoretti S, Wooster R, Pandolfi P, Cantley L. Abstract LB-365: Effective use of PI3K/MTOR and MEK inhibitors prior to hormone ablative therapy in PTEN-loss driven murine prostate cancer Cancer Research 2012, 72: lb-365-lb-365. DOI: 10.1158/1538-7445.am2012-lb-365.
Abstract LB-418: Targeting the PI3K/mTOR pathway in genetically engineered mouse models of prostate cancerPatnaik A, Courtney K, Bellinger G, Lunsford E, Robichaud K, Grant A, Lenkinski R, Pedrosa I, Signoretti S, Wooster R, Cantley L. Abstract LB-418: Targeting the PI3K/mTOR pathway in genetically engineered mouse models of prostate cancer Cancer Research 2011, 71: lb-418-lb-418. DOI: 10.1158/1538-7445.am2011-lb-418.